Document Detail

Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study.
MedLine Citation:
PMID:  23038759     Owner:  NLM     Status:  Publisher    
BackgroundOne million people worldwide benefit from chronic dialysis, with an increased rate in Western countries of 5% yearly. Owing to increased incidence of cancer in dialyzed patients, the management of these patients is challenging for oncologists/nephrologists.Patients and methodsThe CANcer and DialYsis (CANDY) retrospective multicenter study included patients under chronic dialysis who subsequently had a cancer (T0). Patients were followed up for 2 years after T0. Prescriptions of anticancer drugs were studied with regard to their renal dosage adjustment/dialysability.ResultsA total of 178 patients from 12 institutions were included. The mean time between initiation of dialysis and T0 was 30.8 months. Fifty patients had received anticancer drug treatment. Among them, 72% and 82% received at least one drug needing dosage and one drug to be administered after dialysis sessions, respectively. Chemotherapy was omitted or prematurely stopped in many cases where systemic treatment was indicated or was often not adequately prescribed.ConclusionsSurvival in dialysis patients with incident cancer was poor. It is crucial to consider anticancer drug treatment in these patients as for non-dialysis patients and to use current available specific drug management recommendations in order to (i) adjust the dose and (ii) avoid premature elimination of the drug during dialysis sessions.
N Janus; V Launay-Vacher; A Thyss; H Boulanger; O Moranne; M S Islam; J-P Durande; M Ducret; L Juillard; Z Soltani; G Motte; J Rottembourg; G Deray; J Thariat
Related Documents :
23045839 - Warfarin: pharmacological profile and drug interactions with antidepressants.
3052009 - Role of plasma concentration monitoring in the evaluation of response to antiarrhythmic...
7295879 - Age-related differences in ophthalmic drug disposition i. effect of size on the intraoc...
24729909 - Metabotropic glutamate receptor 5 negative modulation in phase i clinical trial: potent...
23932649 - Drug-induced exanthems: correlation of allergy testing with histologic diagnosis.
23522569 - Hepatoxicity of new antiretrovirals: a systematic review.
22935759 - The determination and interpretation of the therapeutic index in drug development.
23045839 - Warfarin: pharmacological profile and drug interactions with antidepressants.
15724099 - The mystical effects of dermatological vehicles.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-4
Journal Detail:
Title:  Annals of oncology : official journal of the European Society for Medical Oncology / ESMO     Volume:  -     ISSN:  1569-8041     ISO Abbreviation:  Ann. Oncol.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007735     Medline TA:  Ann Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Service ICAR-Department of Nephrology, Pitié-Salpêtrière Hospital, Paris.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assi...
Next Document:  Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-i...